Similarly, loss of the transcription factor GATA-binding factor 2 (GATA2) reduces the viability of newly diagnosed non-small-cell lung cancer (NSCLC) cells harboring KRAS mutations, which drive aberrant KRas signaling [104]. Here, KRAS is linked to non-small cell lung carcinoma.